Home › Targets › VEGF-A
VEGF-A (4 companies · 15 programs)
Companies with an active program directed at VEGF-A.
- tovecimig — Biliary Tract Cancer Phase 2
- tovecimig — Colorectal Cancer Phase 2
- CTX-10726 Phase 1
- CTX-10726 — Renal Cell Carcinoma Phase 1
- CTX-10726 — Gastroesophageal Cancer Phase 1
- CTX-10726 — Hepatocellular Carcinoma Phase 1
- CTX-10726 — Endometrial Cancer Phase 1
- tovecimig — Glioblastoma Phase 1
- ivonescimab — Non-Small Cell Lung Cancer NDA Submitted
- ivonescimab — Colorectal Cancer Phase 3
- ivonescimab — Head and Neck Squamous Cell Carcinoma Phase 3
- ivonescimab — Cholangiocarcinoma Phase 3
- 4D-150 — Wet Age-Related Macular Degeneration Phase 3
- 4D-150 — Diabetic Macular Edema Phase 2
- VIS-101 — Wet Age-Related Macular Degeneration Phase 2
